S
Scribe Therapeutics
Focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders
About Scribe Therapeutics
Scribe Therapeutics, operating under the website scribetx.com, is a biotechnology startup that specializes in genetic medicine. The company leverages the revolutionary CRISPR technology to engineer advanced solutions for treating genetic diseases. CRISPR, or Clustered Regularly Interspaced Short Palindromic Repeats, is a gene-editing tool that allows scientists to alter DNA sequences and modify gene function. In simpler terms, it's like a molecular scissor that can cut and paste genes, potentially fixing genetic defects or diseases.
Scribe Therapeutics serves a broad range of clients, including healthcare providers, research institutions, and pharmaceutical companies. It operates in the rapidly growing genetic medicine market, which is expected to reach $10.1 billion by 2026, according to a report by Global Market Insights.
The business model of Scribe Therapeutics is based on developing and licensing its proprietary CRISPR-based genetic medicine platform. The company generates revenue by partnering with other companies to develop gene therapies and by licensing its technology to third parties.
Scribe Therapeutics is also developing novel viral and non-viral delivery technologies to enable in vivo genetic medicine, which means treating diseases inside the body by editing genes. The company's technology is designed for exceptional specificity within the genome, which allows for precise therapeutic interventions and allele-specific targeting. An allele is a variant form of a gene, and targeting specific alleles can potentially treat genetic diseases caused by specific gene variants.
In summary, Scribe Therapeutics is a cutting-edge biotech startup that is pioneering the future of genetic medicine by leveraging advanced CRISPR technology.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2017
- Headquarters
- Alameda, United States
- Employees
- 87
- Open positions
- None listed
- Dealroom signal
- 62.9/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Crispr, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jun 2026 | $25M | — | California Institute for Regenerative Medicine | ↗ |
| CONVERTIBLEOther financing | May 2023 | $0 | — | Prevail Therapeutics | ↗ |
Growth signals
Latest recorded traffic for Scribe Therapeutics is 18K monthly website visits, up 143.2% over the last three months. Scribe Therapeutics's team declined 18.7% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
California Institute for Regenerative Medicine
Series A11 investors entered at this stage
Andreessen Horowitz
Biogen
Avoro Capital Advisors
Wellington Management
OrbiMed
RA Capital Management
Perceptive Advisors
T. Rowe Price
Menlo Ventures- AVAvoro Ventures
Prevail Therapeutics
Other known investors1 additional known investor
University of California, Berkeley
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Scribe Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Scribe Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.